Pages
Monday, October 22, 2012
全球級生產: WuXi AppTec展現抗體藥物 實力 !!!
三星 抗體相似藥SAIT101滑鐵盧 能走得下去嗎?
田辺三菱、長生堂との方針にずれ後発医薬品の資本提携解消
iPS & iPad !!
杏輝 卵巢癌第一學名藥1億市場: 液剋鉑停 (iv)
杏輝 骨鬆第一學名藥4億市場: 雙磷酸鹽+Vit D3
楊育民/ 張有德 缺席 2012科技會報 生技BTC會議 !!!
張有德/ 林榮錦/ 上智創投 開曼成立益安醫材(Aeon International)!!
台灣醫療服務 中國18家推廣平臺
生技政策&業績 缺一不可 !!
益生菌活性胜肽 國家發明獎
中化生醫科技公司技轉國家發明獎 大成報-2012年10月22日 下午20:19 【記者林瑞明/台北報導】根據國民健康局調查,國內20歲以上民眾平均約4人就有1人罹患高血壓,而隨著血壓的升高,發生嚴重心血管疾病(包括心肌梗塞(myocardial infarction)、心臟衰竭(heart failure)、中風(stroke)及腎臟疾病(Kidney disease)等)的危險性也愈高。看準全球高齡化趨勢與三高族群(three hyper population)之廣大需求,中興大學、大葉大學與中化生醫科技股份有限公司共組產學團隊,歷經5年時間,成功開發「新穎抗高血壓肽」成份,已獲准美國、歐洲、台灣和中國的專利。今年更獲得經濟部智慧財產局最高榮譽「國家發明創作獎」殊榮。對於長期深耕健康產業的中化生醫科技公司而言,是一大肯定。10/22中化生醫科技公司舉辦「新穎抗高血壓肽」產品發表,邀請台灣大學名譽教授,同時被譽為台灣發酵乳研究(fermented milk study)之父的林慶文(Lin, Chin-Wen)老師蒞臨指導。前馬偕醫院家醫科醫師、大有診所院長童惟新醫師則講述最新預防保健觀念。中興大學研發長陳全木與大葉大學研發長陳小玲教授更大方分享「新穎抗高血壓肽」研發過程。
中化生醫科技與大葉、中興大學團隊共同投入克弗爾系列保健食品開發 陳小玲教授表示:「新穎抗高血壓肽」的開發關鍵在於結合特殊發酵菌種「克弗爾粒(Kefir grain)」與團隊開發的專利產程,缺一不可。克弗爾是一種酒精發酵乳(alcoholic fermented milk),源自北高加索山,相傳具有神奇的醫療保健功效,在舊蘇聯時代就被醫療院所廣泛應用於替代醫療。跟目前市售的發酵乳(fermented milk)完全不同,不僅含有乳酸菌(Lactobacillus),還有酵母菌(Yeast),菌相(Microflora)非常複雜。目前台灣市場並沒有真正利用克弗爾粒發酵的保健食品上市。陳教授早在乳酸菌製品尚未在台灣風行之時,即跟隨林慶文教授學習,啟發了克弗爾的研究思路;今日,與中化生醫科技公司共同投入克弗爾系列商品開發,「新穎抗高血壓肽」研究成果受到各界肯定,二十年的師徒研究傳承接力,也為台灣杏壇增添佳話。曾榮獲中華民國十大傑出青年、總統農業創新獎、史上最年輕東元獎得主的中興大學研發長陳全木教授也表示:乳來源生物活性肽(bioactive peptides from milk)深具商業應用潛力,而「新穎抗高血壓肽」功效經活體動物實驗(in vivo)驗證(experimental verification),跟一般無法在活體驗證的乳胜肽成份完全不同,天然、安全、無副作用,能夠真正嘉惠民眾健康。中化生醫科技公司李宗勇總經理表示:「這項獨步市場的保健產品,動員中化與中興、大葉大學三方研發團隊,歷經5年、耗資四千萬,完全以生技製藥的規格(biopharmaceutical specifications)打造,展現公司深耕保健食品市場的決心,從基礎原料到研發、製程都是MIT,未來更將推出一系列克弗爾保健食品。目前,「新穎抗高血壓肽」技轉商品已完成功效驗證研究,正準備申請健康食品認證,有信心成為台灣製造、行銷國際的保健食品,造福全人類健康。此外,今年也是中化製藥的60週年,所以這個技術轉移的保健食品也將會成為指標性的商品。」
國家發明創作獎食品 網路通路鋪貨
中化生醫 新藥搶鋪貨【經濟日報╱記者黃文奇/台北報導】 2012.10.23 04:11 am 中化(1701)集團子公司中化生醫昨(22)日發表保健領域新產品「新穎抗高血壓月太」,目前已率先在網路通路鋪貨,並已申請健康食品認證,年內可望進軍一般保健通路。中化為台灣老牌學名藥廠,旗下子公司包括中化合成、中化裕民、蘇州中化、中化生醫等;其中,中化生醫主要產品為家庭保健用品與居家照顧服務事業。中化昨日股價以20.55元平盤做收,該公司今年上半年稅後純益約2.03億元,每股稅後純益為0.69億元。據悉,中化生醫新產品「新穎抗高血壓月太」,是與中興大學、大葉大學所共同研發,該系列保健產品稱之為「克弗爾」,目前已獲准美國、歐洲、台灣和中國的專利。中化生醫表示,該系列產品技術今年獲得經濟部智慧財產局最高榮譽「國家發明創作獎」,由於克弗爾是一種酒精發酵乳,源自北高加索山,相傳具有醫療保健功效,過去在舊蘇聯時代就被醫療院所廣泛應用於替代醫療。【2012/10/23 經濟日報】
ROC sets new course for biotech development
Taiwan biotech sector is set for a significant shot in the arm under stage two of the ROC government's industrywide promotion plan. (CNA) Publication Date:10/18/2012 Source: Taiwan Today ByMeg Chang Cultivating homegrown talent and developing medical care services are central planks in the second phase of the ROC government plan to promote Taiwan's biotechnology sector, Minister without Portfolio Chang Shan-cheng said Oct. 17."The plan for biotechnology development, which commenced in 2009, laid a solid foundation for the local sector," Chang said. "From 2013, the second stage will focus on enhancing Taiwan's talent pool and promoting exports of medical care services."Under the plan, the government will fund an NT$300 million (US$10.26 million) three-year talent training program as a way of sharpening the sector's human resource assets."Taiwan produces 400 graduates with doctoral degrees in biotech-related disciplines every year, four times the average number of openings on offer in the private sector," the minister said, adding that the mismatch bodes ill for industry development.The minister said the government will subsidize local academic and state-funded organizations to create 100 post-doctoral positions in public-private research projects per year. "Such hands-on experience will greatly facilitate the movement of these experts into the private sector."Taiwan has already made tremendous headway in the development of medical devices and pharmaceuticals, Chang said. "Medical care services are a promising field that Taiwan can realistically train its sights on," he said.The government will work with the private sector to identify the kinds of services suitable for export, including turn-key solutions incorporating medical care and information communications technology. It will also encourage the establishment of biotech venture capital firms with funds of between NT$500 million and NT$1 billion."What we plan is the creation of two or three examples of successful investment before setting up mega-funds that require public contribution," Chang said. (JSM)
Biotech Ph.D. holders not the only ones who need help: lawmakers
2012/10/22 22:26:02 Taipei, Oct. 22 (CNA) Lawmakers urged the government Monday to stop favoring holders of doctorate degrees in biotechnology and extend job programs to Ph.D.s in other fields to address the lack of opportunities for highly educated talent in Taiwan.The issue was highlighted after the Executive Yuan approved a program earlier this month to provide 100 jobs to people with Ph.D.s in biotechnology.Under the three-year program, the participants will receive a year of job training that combines theoretical and practical learning at universities or nonprofit organizations and be paid up to NT$1 million (US$34,157) a year before entering the job market.Chiang Nai-shin of the ruling Kuomintang (KMT) party warned that the surplus of talent in the biotech sector is just a tip of the iceberg as only 6 percent of Taiwan's doctorate holders got their degree in biotechnology.The majority hold Ph.D.s in engineering, education, and medicine, and a comprehensive approach should be applied to help all educated jobseekers and ease their difficulties in finding work, he said.KMT lawmaker Lu Yu-ling expressed concern over the level of income offered under the program after a similar project launched for university graduates a few years ago, which only provided a monthly salary of NT$22,000, may have pulled down the average salary for new job entrants.Minister of Education Chiang Wei-ling responded that a number of programs helping highly educated people find jobs and that the suggested pay level was decided by different government agencies.The United Daily News reported Monday that in the biotechnology sector alone, Taiwan currently produces around 400 doctorate degree holders a year, but the private sector creates only 140 jobs per year for them.Wang Li-yun, an associate professor in National Taiwan Normal University's Department of Education, told the paper that developing the biotech industry is costly and the market in Taiwan is relatively limited, meaning that many Ph.D. graduates who don't have work experience end up as salespeople for pharmaceutical companies.The program targeting people holding Ph.D.s in biotechnology has also drawn mixed views among top managers in the high-tech sector, the report said.Chang Yung-sheng, founder of Hi-Q Marine Biotech International Ltd. said he welcomed the new measure and the government's effort to cultivate talent.But other companies hoped the government will extend the training program to over two years as developing a new drug normally takes between 5-10 years, it said. (By Chen Chih-chung and Maia Huang)
TNI BioTech and Hubei Qianjiang Pharmaceuticals Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Marketwire NEW YORK, NY -- (Marketwire) -- 10/18/12 -- TNI BioTech, Inc. (PINKSHEETS: TNIB) and Hubei Qianjiang Pharmaceutical Co., Ltd., a leading Chinese pharmaceutical company, today announced an agreement to co-develop new cancer drugs based on TNI BioTech's patents involving Methionine Enkephalin which when approved will be marketed in China under the brand name IRT-101 and IRT-102. Under the Supervision of Dr. Ronald Herberman, Chief Medical Officer, and Professor Fengping Shan, Chief Science Officer, TNI BioTech, Inc. will maintain oversight responsibility for pre-clinical and clinical trials in China complying with both FDA and SFDA standards. The companies believe this joint development will fast track the drugs for the Chinese pharmaceutical markets. Hubei Qianjiang Pharmaceutical Co., Ltd. has committed a minimum of 10 million yuan, approximately $1,600,000 dollars, for pre-clinical work. The pre-clinical trials, designed to assess safety, tolerability and antitumor activity of Methionine Enkephalin, are required in China as Methionine Enkephalin is a new drug. Once the companies complete pre-clinical studies, TNI BioTech, Inc. will apply for clinical trials with SFDA. Hubei Qianjiang Pharmaceutical Co., Ltd.will provide the funding for clinical trials in China to have Methionine Enkephalin approved as a new drug for the treatment of cancer. Methionine Enkephalin's potential in fighting cancer was identified in completed Phase I and early phase II trials in the United States. During Phase I and Phase II trials, Methionine Enkephalin exhibited encouraging antitumor efficacy and a favorable toxicity profile. "This alliance with TNI BioTech validates Hubei Qianjiang Pharmaceutical Co., Ltd.'s business model of co-developing novel compounds as therapies for Chinese markets in conjunction with a U.S. biotech company," said Mr. Ye Jige, President of Hubei Qianjiang Pharmaceutical Co., Ltd. "The initiation of the pre-clinical trials for IRT-101 and IRT-102 in China is a significant achievement for the development of Hubei Qianjiang Pharmaceutical Co., Ltd. and it represents both an important development milestone for this promising cancer drug and illustrates the benefits of Chinese and Western biopharmaceutical companies working together to efficiently carry out drug development. This important step will expedite the clinical development process of IRT-101 and IRT-102 in China." Noreen Griffin, CEO of TNI BioTech, at the signing ceremony in Qianjiang China said,"This agreement illustrates TNI BioTech's ability to draw upon its patents to build alliances that help biopharmaceutical companies navigate the approval process of new therapies and further illustrates our strategy to maximize the potential of biopharmaceutical development and innovation for the benefit of patients and our shareholders."
About Hubei Qianjiang Pharmaceutical Co., Ltd Hubei Qianjiang Pharmaceutical Co., Ltd. is a Chinese public company established in the 1970s trading on the Shanghai Stock Exchange. The company owns high-tech production and manufacturing and distribution facilities, and a strong research and development department. The Company has passed the GMP certification and can produce 120 different products, including 15 kinds of preparations, such as eye drops, freeze dried injections, tablets, capsules, and cephalosporin powders for injections. The Company has two series of products -- proprietary ophthalmic drugs and anti-infection drugs. The "jing" brand eye drops rank first in market share. The Company manufactures a brand of Acyclovir, clindamycin and other anti-virus products that have received national major new product certification. The "jing" and "gantai" trademarks have become famous brands in China that assure both quality and consumer satisfaction.
About TNI BioTech, Inc. TNI BioTech, Inc. is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases. Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells. However, even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following: Autoimmune states such as rheumatoid arthritis and multiple sclerosis; As an adjunct to antibiotics in the treatment of infectious diseases; In cancer patients undergoing chemotherapy, radiation treatments or surgery; Patients with AIDS, in combination with retroviral drug therapy; and In wound healing or herpes viral infections. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
东京大学为iPS灰头土脸!!
日本东京大学研究员iPS细胞研究造假遭解雇 来源: 新华网日本东京大学19日宣布,对谎称实施了世界首例iPS细胞临床应用的东大医学部附属医院特任研究员森口尚史予以惩戒解雇的处分。近日闹得沸沸扬扬的日本科学界造假风波暂时告一段落。日本京都大学教授山中伸弥和一名英国科学家分享了今年的诺贝尔生理学或医学奖,这也是日本人时隔25年第二次获得该奖项。有意思的是,山中伸弥的"风头"近日大有被森口尚史盖过之势,他谎称自己在美国成功实施了6例由iPS细胞培养而成的心肌细胞的临床移植手术,并成功骗过了日本《读卖新闻》和共同社等主流媒体。然而,造假很快被揭穿,森口尚史的表述被美国马萨诸塞州综合医院和哈佛大学一口否定。《自然》杂志和其他媒体以及专家学者也对此报道提出质疑。森口尚史在穷追猛打之下不得不承认,只在去年6月做过1例移植手术。但他却无法提供相关证据。森口尚史本人落得身败名裂,误报消息的日本媒体也因此灰头土脸。东京大学指出,森口尚史的行为"严重伤害了东京大学的名誉和信用"。森口尚史1964年出生,1989年进入东京医科齿科大学保健卫生学科,1995年获得硕士学位,2007年获得东京大学博士学位。2010年,他担任东京大学医学部附属医院的客座研究员,今年9月被聘为特任研究员,研究方向是冷冻保存脏器和细胞的相关研究,但是他没有取得过医师资格。(记者 蓝建中)
Russia Establishes Clinical Trial Hub Cost and speed play big roles in the country’s increased presence in the market.
Alex PhilippidisInsight & Intelligence™ : Oct 19, 2012More than two years after Vladimir Putin promised to transform his nation into a biotech heavyweight by 2020, Russia is achieving a measure of success by one important barometer, namely a steadily growing volume of clinical trial activity.That was supposed to be the effect of a 2010 law that requires companies looking to market their drugs in Russia to conduct at least some of their clinical trials there. That measure ("On Circulation of Medicines"), however, has drawn criticism from the industry group Association of Clinical Trial Organizations (ACTO) for slowing down clinical trial activity through what it calls overly strict requirements for patient insurance, investigators, and redundant accreditation requirements for conductors of trials. The law is under review by Russia's health commissioner, Veronika Skvortsova, appointed to the post in May.Instead, executives familiar with the market say the uptick in clinical trials reflects more a combination of lower costs, lower regulatory hurdles, and increased public and private investment in drug companies that carry out development work in Russia.On October 10, U.S.-based Cleveland BioLabs and Incuron, a joint venture that is 75.8% owned by the publicly traded company, announced the dosing of the first patient in a Phase I study of the oral formulation of CBL0137 in subjects with advanced solid tumors that resist standard-of-care treatment. The trial is being conducted at five leading oncology centers across the Russian Federation. Incuron is also conducting Phase I trials for the orally administered small cancer drug CBL0102, which is being developed for orphan indications in developing markets.The percentage of Incuron not owned by Cleveland BioLabs is held by the $120 million Russian closed mutual venture fund Bioprocess Capital Ventures, which focuses investment on what it deems innovative pharmaceutical, biotechnology, and fine chemistry projects across the Russian Federation."You need to define when you start—and my definition is, you start with formal preclinical. And in the United States, if you start with this and you're pretty lucky, you're talking about 10 years, maybe more to develop a drug. In Russia, it looks like you can ramp it up in five," Michael Fonstein, Ph.D., president of Cleveland BioLabs, told GEN.
Ease of Recruiting One reason for the shorter timeframe, according to Dr. Fonstein, is quicker clinical trials resulting from the ease of recruiting patients beyond Phase I, the tendency of patients once enrolled to stay on the trials, and the design of trials, which can require smaller Phase III trials of products shown to be effective earlier in clinical practice."If, after clinical practice, you already know the optimal conditions for your drug, and clinical practice is supposed to tell you this, then basically you can do a Phase III trial on a very small number of patients, if you can show strong effect," Dr. Fonstein said. "What we're trying to do is to go to a full drug development cycle in Russia, not just do a fast Phase I trial and license it to somebody and forget, but go from science to clinical practice, and we believe it can be done substantially faster, and substantially cheaper than in the United States."How much cheaper? Less than $100 million, compared with the oft-quoted estimate of $1 billion or more in the U.S., for getting drugs into clinical practice under Russian auspices.According to ACTO, the average period to issue approval to conduct a clinical trial during the first half of 2012 was 118 days —12 days better than a year earlier, but still about two months longer than the period set by law of 41 business days or 57 calendar days.In the first half of this year, according to the quarterly Clinical Trials in Russia "Orange Paper" issued by Synergy Research Group (SynRG), Russia's Ministry of Health approved 477 new clinical trials, compared with 571 in all of last year and 492 in 2010.During the second quarter, according to SynRG, 257 trials were approved, a 44% jump from 178 in Q2 2011. Nearly half the trials approved in Q2 2012 (107 or 42%) were bioequivalence trials, while almost as many (102 or 40%) were multinational multicenter clinical trials; the remainder (48 or 19%) were local clinical trials.
Speed, Quality, and Cost Anna Ravdel, SynRG's director of business development, told GEN that Russia enjoys three strengths as a clinical trials venue: speed, quality, and cost.Patients flock to trials, she said, in order to gain access to the best physicians and medication as well as due to shortcomings of the state healthcare system ranging from limited government reimbursement for medication to the fact the insurance and governmental medical systems do not cover all patients and diseases.The quality of clinical data is high enough to withstand FDA and EMA inspections, with both agencies approving drugs using data collected from Russian sites—13 EMA approvals and an FDA approval during Q2 alone. While Russian drug companies accounted for a plurality of approved clinical trials during the second quarter (115), five global biopharma giants—Roche, Pfizer, AstraZeneca, GlaxoSmithKline, and Teva —were approved for a combined 31 studies totaling 3,916 patients, according to SynRG."We recommend to our clients to include Russia early into their clinical trial program if they have plans in the future to register the drug in Russia, because otherwise, without any patients from Russia, the registrators in the Ministry of Health may require the sponsor to conduct another study in Russia, even though the entire program has been completed," Leon Dzivinsky, senior vp and general counsel for ClinStar, a provider of clinical development services in Russia and Eastern Europe, told GEN.Dzivinsky, whose company is involved at any point in 40 to 50 clinical studies, said Russian clinical trials enjoy faster patient recruitment timeframes—in one instance, saving 17 months or $15 million for one Phase III trial of an advanced breast cancer drug. ClinStar needed just 24 months to recruit 318 patients in Russia, Estonia, Ukraine, and Belarus, vs. 41 months for 542 patients in 18 other nations (none being the U.S).Patients recruited for clinical studies in Russia don't turn over as often as elsewhere: "Whatever the doctor tells the patient, they tend to follow. They treat the doctor as a top authority. And if they start with a particular doctor in an indication, they tend to stick with that doctor throughout the term of their treatment," Dzivinsky said.
"Circulation" Draws Fire Since the early 1990s, clinical trial activity has grown most years and especially since 2005, dipping only in 2010 following the clinical trial law called "On Circulation of Medicines." It transferred authority within the government to the Ministry of Health; set new rules qualifying sites and investigators; and added requirements for sponsors, such as providing life and health insurance for each patient. ACTO argues the law shrunk the market for active investigators by 25%−35% and favors a two-year trial experience minimum, plus a shift to liability insurance for entities organizing and conducting clinical trials.A pair of initiatives announced in recent months aims to keep clinical trial activity humming in Russia. Last month, Maxwell Biotech Venture Fund, founded with participation from the Russian government's Russian Venture Company (RVC) fund of venture funds, approved an undisclosed investment in privately held Osteros Biomedica. Osteros is preparing a proof-of-concept clinical trial program to test the safety and efficacy of its first drug candidate, MBC-11, against multiple myeloma.And in March, Russia's $10 billion state-owned Rusnano technology fund said it would join the U.S. venture capital firm Domain Associates in investing $760 million into U.S. pharmaceutical, diagnostics, and medical device companies, plus creating a manufacturing plant and increasing drug development in Russia.One challenge Russia must overcome in coming years is growing competition for drug trials outside the U.S. or Europe, especially from Russia's fellow-BRIC nations (Brazil, India, and, especially, China), which like Korea have sought to position themselves as lower-cost clinical venues. In addition, Russia's regulators will have to continue progress toward faster decisions on clinical trials, especially now that FDA has signaled through PDUFA V that it will step up the pace of its reviews of trial data and drug applications.
Trial and Error: India can attract 5-10% of the global market for drug trials
Shobha John, TNN | Oct 22, 2012, 09.05AM IST It's an industry waiting to be tapped. But lack of regulation in clinical trials in India is giving it a bad name and making it lose ground to China, Malaysia and Singapore. Often, data of various trials is difficult to find and in some cases, doesn't even exist. So much so that last week the Supreme Court asked the Centre and states to furnish details of clinical trial deaths and the compensation paid to families of victims. This was after a parliamentary committee report said that 2,374 people had died during such trials between January 1, 2007 and June 30, 2012, and that families of only 37 victims had been paid a small compensation. The clinical research market, incidentally, is worth $1.5 billion in India. By 2015, according to Mckinsey and Company, it's expected to be about $20 billion, with a demand for 50,000 professionals. Assocham estimates that India can attract 5-10% of global clinical trials in the next five years.
三福化工新任董事
三福化工(4755) 更正公告本公司101年臨時股東會董監改選名單發言時間 101/10/2217:52:43發言人 巫信弘 發言人職稱 董事長 發言人電話 02-2542-6789 主旨 : 更正公告本公司101年臨時股東會董監改選名單符合條款第6款事實發生日101/10/22說明 1.發生變動日期:101/10/222.舊任者姓名及簡歷:董事:巫信弘三福化工(股)公司董事長董事:張純明三福環球(股)公司董事長董事:張益宗珍綠品(股)公司董事長董事:王耀銘國際日東科技(股)公司總經理董事:傅阿喜中華方大(香港)有限公司顧問監察人: 張雅萍巴西方大(股)公司 董事長監察人: 游勝福明光半導體(股)公司獨立董事監察人: 黃明富允盛投資顧問(股)公司董事長3.新任者姓名及簡歷:董事:巫信弘三福化工(股)公司董事長董事:三福環球股份有限公司代表人張純明三福環球(股)公司董事長董事:張益宗珍綠品(股)公司董事長董事:王耀銘國際日東科技(股)公司總經理董事:蘇天寶國際日東科技(股)公司董事董事:梁國源美國杜克大學經濟學博士元大寶華綜合經濟研究院院長獨立董事:黃育徵賓夕法尼亞大學化學學士新鼎系統股份有限公司 董事獨立董事:李鍾熙美國伊利諾理工學院博士財團法人生物技術開發中心董事長監察人: Pilot Keymark SDN.BHD. 代表人張三福環球(股)公司經理監察人: 游勝福明光半導體(股)公司獨立董事監察人: 黃明富允盛投資顧問(股)公司董事長4.異動原因:配合本公司公開發行後,選任獨立董事之規定及未來營運發展需要,擬提前於101年10月 22日股東臨時會時全面改選。5.新任董事選任時持股數:董事:巫信弘 3,421,750股董事:三福環球股份有限公司 22,116,689股董事:張益宗 255,341股董事:王耀銘 300,000股董事:蘇天寶 50,000股 董事:梁國源 0股 獨立董事:黃育徵 0股 獨立董事:李鍾熙 0股 監察人: Pilot Keymark SDN.BHD. 19,929,000股監察人: 游勝福 0股監察人: 黃明富 0股6.原任期(例xx/xx/xx至xx/xx/xx):099/03/23~102/03/227.新任生效日期:101/10/228.同任期董事變動比率:不適用9.其他應敘明事項:無以上資料均由各公司依發言當時所屬市場別之規定申報後,由本系統對外公佈,資料如有虛偽不實,均由該公司負責.
Taiwanese-made blood pressure supplement launched
By Lee Yu-hsin and Jake Chung/Staff reporter, with Staff writerA new health supplement to tackle high blood pressure that was jointly developed by National Chung Hsing University, Da Yeh University and researchers from the pharmaceutical industry was introduced yesterday at a product launch. According to the Da Yeh University research team's director, Chen Hsiao-ling (陳小玲), statistics from the Department of Health (DOH) indicate that one out of four people over the age of 20 has high blood pressure. If left uncontrolled, high blood pressure could lead to serious cardiovascular diseases, Chen said. Chen said that research teams from the two universities cooperated with teams from China Chemical and Pharmaceutical Co and the company's affiliate, Chunghwa Biomedical Technology Co, in a five-year-long research venture to produce a new peptide from kefir grains. Kefir grains are a mix of bacteria and yeasts in a matrix of proteins, lipids and sugars traditionally added to goat or cow milk to make the milk drink kefir. Peptides are short polymers of amino acid monomers linked by chemical reactions between carboxyl-amino groups of two molecules. The purified anti-hypertensive peptide developed and extracted from kefir grains by the team provide a substance that helps lower blood pressure, National Chung Hsing University research team director Chen Chuan-mu (陳全木) said. According to the Ministry of Education's Web page, Chen also said that the peptide was very versatile and could be used extensively in other pharmaceutical products. If legally permitted, the peptide could be combined with the research team's patented mammary gland-specific expression platform to raise cows and goats that have the peptide inherently in their systems, allowing more people to ingest the peptide through cow's or goat's milk, Chen said. As more than 70 percent of health products in the nation are reliant on foreign imports, Chen said if the peptide is successfully manufactured, Taiwan would own the intellectual property rights to a product that can be locally made and enable Taiwan to break into the international health product market. The invention was awarded a silver medal this year by the Ministry of Economic Affairs' intellectual property office and has been granted patents in the US, some European countries, Taiwan and China.
台南觀光醫美!!!
大台南觀光聯盟推動醫美觀光行程【聯合報╱記者修瑞瑩/即時報導】 2012.10.22 10:20 pm 大台南觀光聯盟今天發表台南醫美觀光行程,目前擔任聯盟理事長、同時也是台南市醫師公會理事長王正坤,也是皮膚科醫師,他表示,台南除了美食與古蹟吸引人,高品質與便宜的醫療也是一大賣點,希望能爭取更多觀光客到台南邊玩邊美容。【2012/10/22 聯合報】
幹細胞諾貝爾醫學獎 亞洲國家熱!!!
泰幹細胞研究 資金計畫兩缺【中央社╱曼谷22日專電】 2012.10.22 06:25 pm 諾貝爾醫學獎今年頒給研究幹細胞的英日學者,泰國也開始注意到泰國幹細胞研究的進展,但缺乏資金與國家計畫藍圖。泰國「民族報」(The Nation)今天報導,英國古爾登和日本山中伸彌獲得諾貝爾獎激勵全球再生科學家,包括泰國的幹細胞研究者。但報導指出,回顧泰國研究環境,泰國科學家感嘆,當地的技術環境缺乏方向與資金支持。泰國今年來至少有3家醫院宣布在幹細胞研究上有一定的進展。朱拉隆功大學(ChulalongkornUniversity)今年初宣布朱大是泰國第一家生產人類胚胎幹細胞的機構,建立泰國第一個幹細胞銀行。警察總醫院(Police General Hospital)也研發成人幹細胞治療關節炎病人,醫院現在正針對60名45歲到60歲關節炎病人進行臨床試驗,預估明年完成。馬奚杜大學(Mahidol University)的詩麗拉醫院(Siriraj Hospital)研究團隊上週也宣布發現從人類羊膜液抽取純幹細胞的方法,可逐步治療各種嚴重病症,例如關節炎。報導指出,多數機構只能靠自有資金建立實驗室進行研究,政府僅提供部分資金。警察總醫院主任容傑(Jongjet Aojanepong)表示,政府從未關注支持科學研究,他們必須自行籌資進行幹細胞研究。容傑表示,幹細胞將是未來重要的治療方法,「我們需要一個正式的論壇一起看到未來」。報導指出,泰國幹細胞研究雖然興盛,但卻沒有一個中央機構系統性地管理研究預算,並規劃幹細胞研究方向。負責監督全泰研究的泰國國家研究委員會(National Research Council of Thailand)秘書長蘇提彭(Soottiporn Chittrmittrapap)表示,泰國今年底前會規劃出幹細胞研究藍圖,邀請專家提供意見。有專家建議,應該讓教育機構領導構思,訂出國家目標、策略、方向與財務支持。【2012/10/22 中央社】
印度將免費提供學名藥給數億人民
India to give free generic drugs to hundreds of millions Tue, Oct 23, 2012 -India has put in place a US$5.4 billion (NT$157.6 billion) policy to provide free medicine to its people. From city hospitals to tiny rural clinics, India's public doctors will soon be able to prescribe free generic drugs to all comers, vastly expanding access to medicine in a country where public spending on health was just US$4.50 per person last year. Under the plan, doctors will be limited to a generics-only drug list and face punishment for prescribing branded medicines, a major disadvantage for pharmaceutical giants in one of the world's fastest-growing drug markets. "Without a doubt, it is a considerable blow to an already beleaguered industry, " said KPMG partner Chris Stirling. But the initiative would overhaul a system where healthcare is often a luxury, despite 40 percent of the people living below the poverty line, or US$1.25 a day or less. Within five years, up to half of India's 1.2 billion people are likely to take advantage of the scheme, the government says. Others are likely to continue visiting private hospitals and clinics, where the scheme will not operate. (Reuters) 印度已實施一項價值高達五十四億美元(新台幣一千五百七十六億元)的政策,以提供免費藥物給人民。 從城市醫院到鄉村小診所,印度公立醫院醫師不久將可以開免費的學名藥給所有求診者,在健康支出去年每人僅四點五美元的國家,這項措施大幅擴展藥物的取得。 在此計畫下,醫師用藥將限定在名單上的學名藥,開專利藥將面臨處罰。在這個全球藥物市場成長最快速的地區,此舉將讓藥廠巨擘蒙受重大損失。 安侯建業聯合會計師事務所合夥人史特林說:「無疑地,這對已受困的產業是重大打擊。」 不過這項創舉將大幅改革(印度醫療)制度,在該制度中,健康照護通常十分昂貴,儘管百分之四十的人民生活在貧窮線以下,或者每日生活費一點二五美元或更少。 五年內,印度十二億人口中高達半數人民可能受惠於這項計畫,政府指出。其他人可能繼續到民營醫院與診所就醫,該項計畫將不在這些醫療院所運作。 (路透/翻譯:魏國金)
錫安醫療(祈安醫療控股): 中國醫療轉介&月子中心
貿協推廣海外醫療平台 前3季逾6萬海外人士來台使用醫療服務 2012/10/22鉅亨網提供外貿協會建置海外醫療服務平台成效逐步顯現,貿協今天表示,透過台灣於海外醫療服務平台-廣州錫安醫療健康管理中心的安排,10月份共邀請16位陸客來台健檢,團員來自北京、杭州、廣東、吉林、貴州、雲南等地,多數是第一次來台;目前外貿協會已於上海、北京、廣州、洛杉磯、溫哥華、澳洲、柬埔寨等目標市場設置18家國際醫療轉介平台,截至今年第3季,已有逾6萬人海外人士來台使用我醫療服務,其中健檢、醫美項目約占3成、約逾1萬8000人。 外貿協會服務業推廣中心主任張正芬指出,多數來台使用健檢、醫美服務的人士皆透過海外平台轉介,平台效益已漸顯現,我國設置的海外醫療平台,包括醫療中心、政府駐外單位及旅遊業者,遍布全球,提供醫療轉介及簡易諮詢服務,除擴大醫療服務輸出,更宣傳台灣服務業形象。張正芬補充,陸客之前會藉觀光、商務會議來台,順道使用醫美健檢服務,在我國政府開放醫療簽證後,來台使用健檢與醫美二項醫療服務的陸客人數明顯增加。台灣健檢設備先進新穎、醫護人員親切,與大陸醫院的氣氛明顯不同,故受陸客青睞。錫安總經理蕭義焜表示,團員已安排在敏盛醫院進行健檢,該院是台灣首家通過國際醫院評鑑認證(JCI),更於2008 年榮獲新制評鑒特優醫院,提供客製化服務及頂級健檢套餐。錫安醫療健康管理中心是我國首次建置的海外醫療轉介平台,於中國大陸耕耘多年,今年6月24日成立祈安醫療科技國際控股集團,並在廣州舉辦啟動上市活動。 該中心規劃在未來兩年於南京、杭州、成都、福州等地開辦分支機構,另外,也將聘請婦產科專科醫師,在廣州市開辦坐月子中心,主打中國大陸頂級客源,訂於明(2013)年初開幕。另外,錫安致力建立兩岸醫事交流平台,繼去(2011)年首次辦理「穗台醫療論壇」,第二屆「穗台醫療論壇」將於今年12月2日至5日於廣州市舉行,屆時廣州市台辦、外貿協會、廣州市衛生局、廣州市醫學會及兩岸醫療機構副院長級代表均會出席此會。
2012 BTC會議…醫療服務產業化 !!
施振榮揪團 醫學中心攻陸【經濟日報╱記者黃文奇/台北報導】 2012.10.23 03:44 am智融集團董事長施振榮。行政院科技會報將於今(23)日召開「2012年生技產業策略會議(BTC)」,「醫療管理服務輸出(海外)」將是明年政策的新主軸;經由智融集團董事長施振榮促成,由生策會集合10餘家醫學中心成立「醫療服務產業化、國際化促進委員會」,搶攻國際醫療管理商機。 行政院科技會報今天起一連3天舉行生技產業策略會議,首度將「醫療管理服務輸出」納入會議主軸,這個會議每年邀集海內外生醫專家與會,會議共識向來成為行政院隔年的生醫政策,「生技起飛鑽石行動方案」就是由這個會議所催生。科技會報表示,今年生技產業策略會議探討的主軸「醫療管理服務輸出」,將於24日進行討論,施振榮即是討論人之一,會後則由民間組成「醫療管理服務輸出平台」,媒合台灣醫院管理進軍國際市場。生策會表示,BTC會議閉幕後,將參考議討論出的結論,邀集台大、榮總、馬偕、陽明、秀傳、嘉基、童綜合等大型醫院,在11月成立「醫療服務產業化國際化促進委員會」,委員會成員除了施振榮外,還將邀集醫務管理協會、時代基金會及各大醫院負責人或院長,共同擔任委員會委員。智融集團說明,施振榮看好「醫療管理服務」,他認為,台灣醫療管理優於亞洲甚至世界各國,未來希望結合雲端、電子(e)化管理系統,做到「整廠輸出」,目標則鎖定大陸市場。據悉,目前智融集團透過旗下智融美洲及智融創新等創投,已開始投資醫療管理公司,未來結合國內醫療院所,研討進一步投資的可能性。智融指出,透過台灣醫療管理優勢,結合數位醫療(雲端)管理系統,台灣可成立醫管服務公司,針對技術、設備輸出,並協助境外醫院改善醫療流程,並提供管理的授權與訓練,不僅可將技術核心留在台灣,也可打造軟、硬體產業鏈。智融集團表示,施振榮對科技事業、旗下創投事業並不直接干涉,但對「醫療管理」投資布局卻是「親力親為」,顯示其重視程度。 【2012/10/23 經濟日報】